Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
Yvonne BrandbergHemming JohanssonMats HellströmMichael GnantVolker MöbusRichard GreilTheodoros FoukakisJonas Berghnull nullPublished in: Breast cancer research and treatment (2020)
clinicaltrials.gov Identifier: NCT00798070; isrctn.org Identifier: ISRCTN39017665.